Sabrina Zidi1, Mouna Stayoussef1, Feryel K Sontini2, Amel Mezlini2, Besma Yacoubi-Loueslati1, Wassim Y Almawi3,4. 1. Laboratory of Mycology, Pathologies and Biomarkers (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar, 1060, Tunis, Tunisia. 2. Salah Azaiez Institute of Oncology, Tunis, Tunisia. 3. Laboratory of Mycology, Pathologies and Biomarkers (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar, 1060, Tunis, Tunisia. wassim.almawi@outlook.com. 4. Department of Biomedical Sciences, Nazarbayev University School of Medicine, Z05K4F4, Nur-Sultan, Kazakhstan. wassim.almawi@outlook.com.
Abstract
BACKGROUND: Ovarian cancer (OC) is one of the most common gynecologic cancers,with significant morbidity and mortality. The risk of OC is influenced by hormone status, of which sex hormone-binding globulin (SHBG), which influences the serum availability of steroid sex hormones, is implicated in the pathogenesis and evolution of OC. The aim of this study is to evaluate the involvement of common SHBG gene variants in OC susceptibility and evolution. MATERIALS: A case control study including 71 OC patients and 74 cancer-free controls, who were genotyped for rs9898876, rs13894, rs1799941 and rs6257 SHBG SNP. Genotyping was done by the allelic discrimination method, using VIC- and FAM-labeled primers. RESULTS: The minor allele frequencies of rs9898876, rs13894, rs1799941 and rs6257 SHBG SNP was comparable between OC cases and control women, implying no significant associations of the tested variants and overall OC risk. Taking homozygous wild-type genotype as reference (OR = 1.00), heterozygous rs9898876 (G/T), and minor allele-carrying genotypes [G/T + T/T] were associated with reduced risk of OC. While rs9898876 heterozygosity (G/T) was predictive of OC occurrence, no significant association of the remaining three tested SNPs was noted with altered risk of OC. Irrespective of FIGO staging, the four tested SHBG SNPs were not associated with the clinical progression of OC. CONCLUSIONS: In conclusion, SHBG rs9898876 is associated with a decreased risk of OC, and thus constitutes a potential diagnostic biomarker of OC.
BACKGROUND: Ovarian cancer (OC) is one of the most common gynecologic cancers,with significant morbidity and mortality. The risk of OC is influenced by hormone status, of which sex hormone-binding globulin (SHBG), which influences the serum availability of steroid sex hormones, is implicated in the pathogenesis and evolution of OC. The aim of this study is to evaluate the involvement of common SHBG gene variants in OC susceptibility and evolution. MATERIALS: A case control study including 71 OC patients and 74 cancer-free controls, who were genotyped for rs9898876, rs13894, rs1799941 and rs6257 SHBG SNP. Genotyping was done by the allelic discrimination method, using VIC- and FAM-labeled primers. RESULTS: The minor allele frequencies of rs9898876, rs13894, rs1799941 and rs6257 SHBG SNP was comparable between OC cases and control women, implying no significant associations of the tested variants and overall OC risk. Taking homozygous wild-type genotype as reference (OR = 1.00), heterozygous rs9898876 (G/T), and minor allele-carrying genotypes [G/T + T/T] were associated with reduced risk of OC. While rs9898876 heterozygosity (G/T) was predictive of OC occurrence, no significant association of the remaining three tested SNPs was noted with altered risk of OC. Irrespective of FIGO staging, the four tested SHBG SNPs were not associated with the clinical progression of OC. CONCLUSIONS: In conclusion, SHBG rs9898876 is associated with a decreased risk of OC, and thus constitutes a potential diagnostic biomarker of OC.
Authors: Ahmed Elattar; Katharine G Warburton; Asima Mukhopadhyay; Rebecca M Freer; Fadhel Shaheen; Paul Cross; E Ruth Plummer; Craig N Robson; Richard J Edmondson Journal: Gynecol Oncol Date: 2011-10-15 Impact factor: 5.482
Authors: Helena Schock; Heljä-Marja Surcel; Anne Zeleniuch-Jacquotte; Kjell Grankvist; Hans-Åke Lakso; Renée Turzanski Fortner; Rudolf Kaaks; Eero Pukkala; Matti Lehtinen; Paolo Toniolo; Eva Lundin Journal: Endocr Relat Cancer Date: 2014 Impact factor: 5.678
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Montserrat Garcia-Closas; Louise A Brinton; Jolanta Lissowska; Douglas Richesson; Mark E Sherman; Neonila Szeszenia-Dabrowska; Beata Peplonska; Robert Welch; Meredith Yeager; Witold Zatonski; Stephen J Chanock Journal: BMC Cancer Date: 2007-04-05 Impact factor: 4.430